US2018037648A1PendingUtilityA1
Methods for treating melanoma
Est. expiryOct 8, 2024(expired)· nominal 20-yr term from priority
A61P 35/00A61P 37/02A61P 37/00A61P 35/02A61P 37/04A61P 3/10A61P 29/00A61P 1/00A61P 19/02A61P 1/16A61P 15/08C07K 2317/30C07K 2317/76A61K 38/22A61K 38/16A61K 38/02A61K 38/1796A61K 2039/505A61K 38/2264A61K 45/06A61N 5/10C07K 16/26A61K 39/3955C07K 16/2869C07K 14/72C07K 14/5759A61P 17/06
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for treating melanoma and other indications by inhibiting leptin activity.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for treating melanoma, comprising:
administering to a human patient having melanoma, a therapeutically effective amount of a protein that binds to and antagonizes leptin, wherein the protein is selected from the group consisting of an antibody, an antibody fragment and a soluble receptor for leptin.
2 . The method of claim 1 , wherein the protein is an antibody or antibody fragment that binds to and antagonizes leptin.
3 . The method of claim 2 , wherein the protein is a monoclonal antibody or a fragment of a monoclonal antibody.
4 . The method of claim 1 , wherein the protein is a soluble receptor for leptin.
5 . A method for treating melanoma, comprising:
administering to a human patient having melanoma, a therapeutically effective amount of a protein that binds to and antagonizes a leptin receptor, wherein the protein is selected from the group consisting of an antibody and an antibody fragment.
6 . The method of claim 5 , wherein the protein is an antibody or antibody fragment that binds to and antagonizes the leptin receptor.
7 . The method of claim 6 , wherein the protein is a monoclonal antibody or a fragment of a monoclonal antibody.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.